FDA 483 - Boston University National Emerging Infectious Disease Laboratories - May 16, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
The FDA inspected Boston University National Emerging Infectious Disease Laboratories, a nonclinical laboratory in Boston, MA, and identified significant deficiencies. Observations included failures in quality assurance review of study reports, unauthorized deviations from standard operating procedures, inadequate archiving of raw data, and insufficient validation of electronic systems. These issues collectively point to concerns regarding data integrity and overall study management practices.
- Inspection Date
- May 16, 2025
- Product Type
- Biologics
ID · 90cabdcc-1217-4b4c-b6cd-4dc915181c12